Possible Association Between 3,4-Methylenedioxymethamphetamine Abuse and Valvular Heart Disease
Valvular heart disease, inducing valvular regurgitation, has been described in users of drugs such as anorectic agents and ergot derivates. 3,4-Methylenedioxymethamphetamine (MDMA; “ecstasy”) also leads in vitro to the proliferation of cardiac valvular interstitial cells by activation of the 5-hydro...
Gespeichert in:
| Veröffentlicht in: | The American journal of cardiology 2007-11, Vol.100 (9), p.1442-1445 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1445 |
|---|---|
| container_issue | 9 |
| container_start_page | 1442 |
| container_title | The American journal of cardiology |
| container_volume | 100 |
| creator | Droogmans, Steven, MD Cosyns, Bernard, MD D’haenen, Hugo, MD, PhD Creeten, Edwin, MD Weytjens, Caroline, MD Franken, Philippe R., MD, PhD Scott, Benjamin, MD Schoors, Danny, MD, PhD Kemdem, Arsène, MD Close, Laurent, MD Vandenbossche, Jean-Luc, MD, PhD Bechet, Serge, MD, PhD Van Camp, Guy, MD, PhD |
| description | Valvular heart disease, inducing valvular regurgitation, has been described in users of drugs such as anorectic agents and ergot derivates. 3,4-Methylenedioxymethamphetamine (MDMA; “ecstasy”) also leads in vitro to the proliferation of cardiac valvular interstitial cells by activation of the 5-hydroxytryptamine 2B receptor. The aim of this study was to determine the occurrence of valvulopathy in young adults taking MDMA. Twenty-nine subjects using or having used MDMA and 29 gender- and age-matched controls were blindly evaluated with echocardiography. Eight subjects (28%) who took MDMA had abnormal echocardiographic results using the United States Food and Drug Administration’s criteria for appetite suppressant–induced valvular heart disease, compared with none in the control group (p = 0.0045). Six (21%) subjects had mitral regurgitation of 1/4 and 4 (14%) of ≥2/4, compared with none in the control group (p = 0.002). The mean mitral regurgitant area ratios (jet/atrium) were 12 ± 9.8% and 5 ± 1.3%, respectively (p = 0.007). Tricuspid regurgitation ≥2/4 was present in 13 MDMA users (45%) and absent in controls (p |
| doi_str_mv | 10.1016/j.amjcard.2007.06.045 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_230369514</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0002914907014634</els_id><sourcerecordid>1374412131</sourcerecordid><originalsourceid>FETCH-LOGICAL-c475t-af4860c7ead9b58c34ff493501ef8a30541769d4e4a493851ed952f9bf6c95073</originalsourceid><addsrcrecordid>eNqFkllv1DAQgC0EotvCTwBFSLw1YRwfiV9ApRxFKgKJ49WaOBPVIcdiJ4X993i1KyrxwpM11jfXp2HsCYeCA9cv-gLH3mFoixKgKkAXINU9tuF1ZXJuuLjPNgBQ5oZLc8JOY-xTyLnSD9kJr4yCGtSG2c9zjL4ZKLuIcXYeFz9P2WtafhFNmTiX-UdabnYDTdT6-fduTBGO2xtacPRTymrWSBlObfYdh9t1wJBdEYYle-MjYaRH7EGHQ6THx_eMfXv39uvlVX796f2Hy4vr3MlKLTl2stbgKsLWNKp2QnadNEIBp65GAUrySptWksT0XStOrVFlZ5pOu7RKJc7Ys0PdbZh_rhQX289rmFJLWwoQ2iguE6QOkAtp60Cd3QY_YthZDnZv1fb2aNXurVrQNllNeU-PxddmpPYu66gxAc-PAEaHQxdwcj7ecaYUupYica8OHCUVt56Cjc7T5JLbQG6x7ez_O8rLfyq4wU8-Nf1BO4p_l-Y2lhbsl_0J7C8AKuBSCyn-ALz0rKc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>230369514</pqid></control><display><type>article</type><title>Possible Association Between 3,4-Methylenedioxymethamphetamine Abuse and Valvular Heart Disease</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Droogmans, Steven, MD ; Cosyns, Bernard, MD ; D’haenen, Hugo, MD, PhD ; Creeten, Edwin, MD ; Weytjens, Caroline, MD ; Franken, Philippe R., MD, PhD ; Scott, Benjamin, MD ; Schoors, Danny, MD, PhD ; Kemdem, Arsène, MD ; Close, Laurent, MD ; Vandenbossche, Jean-Luc, MD, PhD ; Bechet, Serge, MD, PhD ; Van Camp, Guy, MD, PhD</creator><creatorcontrib>Droogmans, Steven, MD ; Cosyns, Bernard, MD ; D’haenen, Hugo, MD, PhD ; Creeten, Edwin, MD ; Weytjens, Caroline, MD ; Franken, Philippe R., MD, PhD ; Scott, Benjamin, MD ; Schoors, Danny, MD, PhD ; Kemdem, Arsène, MD ; Close, Laurent, MD ; Vandenbossche, Jean-Luc, MD, PhD ; Bechet, Serge, MD, PhD ; Van Camp, Guy, MD, PhD</creatorcontrib><description>Valvular heart disease, inducing valvular regurgitation, has been described in users of drugs such as anorectic agents and ergot derivates. 3,4-Methylenedioxymethamphetamine (MDMA; “ecstasy”) also leads in vitro to the proliferation of cardiac valvular interstitial cells by activation of the 5-hydroxytryptamine 2B receptor. The aim of this study was to determine the occurrence of valvulopathy in young adults taking MDMA. Twenty-nine subjects using or having used MDMA and 29 gender- and age-matched controls were blindly evaluated with echocardiography. Eight subjects (28%) who took MDMA had abnormal echocardiographic results using the United States Food and Drug Administration’s criteria for appetite suppressant–induced valvular heart disease, compared with none in the control group (p = 0.0045). Six (21%) subjects had mitral regurgitation of 1/4 and 4 (14%) of ≥2/4, compared with none in the control group (p = 0.002). The mean mitral regurgitant area ratios (jet/atrium) were 12 ± 9.8% and 5 ± 1.3%, respectively (p = 0.007). Tricuspid regurgitation ≥2/4 was present in 13 MDMA users (45%) and absent in controls (p <0.001). The mean tricuspid regurgitant area ratios were 19 ± 9.5% and 9 ± 4.5%, respectively (p <0.001). Four MDMA users (14%) had mild aortic regurgitation (p = 0.11). Valvular “strands” were present in 6 MDMA users (21%) and in none of the controls (p = 0.02). In conclusion, MDMA may lead to mild to moderate valvular heart disease and valvular strands.</description><identifier>ISSN: 0002-9149</identifier><identifier>EISSN: 1879-1913</identifier><identifier>DOI: 10.1016/j.amjcard.2007.06.045</identifier><identifier>PMID: 17950805</identifier><identifier>CODEN: AJCDAG</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Adult ; Biological and medical sciences ; Cardiology ; Cardiology. Vascular system ; Cardiovascular ; Cardiovascular disease ; Dose-Response Relationship, Drug ; Drug abuse ; Ecstasy ; Endocardial and cardiac valvular diseases ; Female ; Hallucinogens - adverse effects ; Heart ; Heart Valve Diseases - chemically induced ; Humans ; Logistic Models ; Male ; Medical sciences ; N-Methyl-3,4-methylenedioxyamphetamine - adverse effects ; Substance-Related Disorders - complications ; Young adults</subject><ispartof>The American journal of cardiology, 2007-11, Vol.100 (9), p.1442-1445</ispartof><rights>Elsevier Inc.</rights><rights>2007 Elsevier Inc.</rights><rights>2007 INIST-CNRS</rights><rights>Copyright Elsevier Sequoia S.A. Nov 1, 2007</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c475t-af4860c7ead9b58c34ff493501ef8a30541769d4e4a493851ed952f9bf6c95073</citedby><cites>FETCH-LOGICAL-c475t-af4860c7ead9b58c34ff493501ef8a30541769d4e4a493851ed952f9bf6c95073</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.amjcard.2007.06.045$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19236843$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17950805$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Droogmans, Steven, MD</creatorcontrib><creatorcontrib>Cosyns, Bernard, MD</creatorcontrib><creatorcontrib>D’haenen, Hugo, MD, PhD</creatorcontrib><creatorcontrib>Creeten, Edwin, MD</creatorcontrib><creatorcontrib>Weytjens, Caroline, MD</creatorcontrib><creatorcontrib>Franken, Philippe R., MD, PhD</creatorcontrib><creatorcontrib>Scott, Benjamin, MD</creatorcontrib><creatorcontrib>Schoors, Danny, MD, PhD</creatorcontrib><creatorcontrib>Kemdem, Arsène, MD</creatorcontrib><creatorcontrib>Close, Laurent, MD</creatorcontrib><creatorcontrib>Vandenbossche, Jean-Luc, MD, PhD</creatorcontrib><creatorcontrib>Bechet, Serge, MD, PhD</creatorcontrib><creatorcontrib>Van Camp, Guy, MD, PhD</creatorcontrib><title>Possible Association Between 3,4-Methylenedioxymethamphetamine Abuse and Valvular Heart Disease</title><title>The American journal of cardiology</title><addtitle>Am J Cardiol</addtitle><description>Valvular heart disease, inducing valvular regurgitation, has been described in users of drugs such as anorectic agents and ergot derivates. 3,4-Methylenedioxymethamphetamine (MDMA; “ecstasy”) also leads in vitro to the proliferation of cardiac valvular interstitial cells by activation of the 5-hydroxytryptamine 2B receptor. The aim of this study was to determine the occurrence of valvulopathy in young adults taking MDMA. Twenty-nine subjects using or having used MDMA and 29 gender- and age-matched controls were blindly evaluated with echocardiography. Eight subjects (28%) who took MDMA had abnormal echocardiographic results using the United States Food and Drug Administration’s criteria for appetite suppressant–induced valvular heart disease, compared with none in the control group (p = 0.0045). Six (21%) subjects had mitral regurgitation of 1/4 and 4 (14%) of ≥2/4, compared with none in the control group (p = 0.002). The mean mitral regurgitant area ratios (jet/atrium) were 12 ± 9.8% and 5 ± 1.3%, respectively (p = 0.007). Tricuspid regurgitation ≥2/4 was present in 13 MDMA users (45%) and absent in controls (p <0.001). The mean tricuspid regurgitant area ratios were 19 ± 9.5% and 9 ± 4.5%, respectively (p <0.001). Four MDMA users (14%) had mild aortic regurgitation (p = 0.11). Valvular “strands” were present in 6 MDMA users (21%) and in none of the controls (p = 0.02). In conclusion, MDMA may lead to mild to moderate valvular heart disease and valvular strands.</description><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Cardiology</subject><subject>Cardiology. Vascular system</subject><subject>Cardiovascular</subject><subject>Cardiovascular disease</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug abuse</subject><subject>Ecstasy</subject><subject>Endocardial and cardiac valvular diseases</subject><subject>Female</subject><subject>Hallucinogens - adverse effects</subject><subject>Heart</subject><subject>Heart Valve Diseases - chemically induced</subject><subject>Humans</subject><subject>Logistic Models</subject><subject>Male</subject><subject>Medical sciences</subject><subject>N-Methyl-3,4-methylenedioxyamphetamine - adverse effects</subject><subject>Substance-Related Disorders - complications</subject><subject>Young adults</subject><issn>0002-9149</issn><issn>1879-1913</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkllv1DAQgC0EotvCTwBFSLw1YRwfiV9ApRxFKgKJ49WaOBPVIcdiJ4X993i1KyrxwpM11jfXp2HsCYeCA9cv-gLH3mFoixKgKkAXINU9tuF1ZXJuuLjPNgBQ5oZLc8JOY-xTyLnSD9kJr4yCGtSG2c9zjL4ZKLuIcXYeFz9P2WtafhFNmTiX-UdabnYDTdT6-fduTBGO2xtacPRTymrWSBlObfYdh9t1wJBdEYYle-MjYaRH7EGHQ6THx_eMfXv39uvlVX796f2Hy4vr3MlKLTl2stbgKsLWNKp2QnadNEIBp65GAUrySptWksT0XStOrVFlZ5pOu7RKJc7Ys0PdbZh_rhQX289rmFJLWwoQ2iguE6QOkAtp60Cd3QY_YthZDnZv1fb2aNXurVrQNllNeU-PxddmpPYu66gxAc-PAEaHQxdwcj7ecaYUupYica8OHCUVt56Cjc7T5JLbQG6x7ez_O8rLfyq4wU8-Nf1BO4p_l-Y2lhbsl_0J7C8AKuBSCyn-ALz0rKc</recordid><startdate>20071101</startdate><enddate>20071101</enddate><creator>Droogmans, Steven, MD</creator><creator>Cosyns, Bernard, MD</creator><creator>D’haenen, Hugo, MD, PhD</creator><creator>Creeten, Edwin, MD</creator><creator>Weytjens, Caroline, MD</creator><creator>Franken, Philippe R., MD, PhD</creator><creator>Scott, Benjamin, MD</creator><creator>Schoors, Danny, MD, PhD</creator><creator>Kemdem, Arsène, MD</creator><creator>Close, Laurent, MD</creator><creator>Vandenbossche, Jean-Luc, MD, PhD</creator><creator>Bechet, Serge, MD, PhD</creator><creator>Van Camp, Guy, MD, PhD</creator><general>Elsevier Inc</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TS</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>M7Z</scope><scope>NAPCQ</scope><scope>P64</scope></search><sort><creationdate>20071101</creationdate><title>Possible Association Between 3,4-Methylenedioxymethamphetamine Abuse and Valvular Heart Disease</title><author>Droogmans, Steven, MD ; Cosyns, Bernard, MD ; D’haenen, Hugo, MD, PhD ; Creeten, Edwin, MD ; Weytjens, Caroline, MD ; Franken, Philippe R., MD, PhD ; Scott, Benjamin, MD ; Schoors, Danny, MD, PhD ; Kemdem, Arsène, MD ; Close, Laurent, MD ; Vandenbossche, Jean-Luc, MD, PhD ; Bechet, Serge, MD, PhD ; Van Camp, Guy, MD, PhD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c475t-af4860c7ead9b58c34ff493501ef8a30541769d4e4a493851ed952f9bf6c95073</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Cardiology</topic><topic>Cardiology. Vascular system</topic><topic>Cardiovascular</topic><topic>Cardiovascular disease</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug abuse</topic><topic>Ecstasy</topic><topic>Endocardial and cardiac valvular diseases</topic><topic>Female</topic><topic>Hallucinogens - adverse effects</topic><topic>Heart</topic><topic>Heart Valve Diseases - chemically induced</topic><topic>Humans</topic><topic>Logistic Models</topic><topic>Male</topic><topic>Medical sciences</topic><topic>N-Methyl-3,4-methylenedioxyamphetamine - adverse effects</topic><topic>Substance-Related Disorders - complications</topic><topic>Young adults</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Droogmans, Steven, MD</creatorcontrib><creatorcontrib>Cosyns, Bernard, MD</creatorcontrib><creatorcontrib>D’haenen, Hugo, MD, PhD</creatorcontrib><creatorcontrib>Creeten, Edwin, MD</creatorcontrib><creatorcontrib>Weytjens, Caroline, MD</creatorcontrib><creatorcontrib>Franken, Philippe R., MD, PhD</creatorcontrib><creatorcontrib>Scott, Benjamin, MD</creatorcontrib><creatorcontrib>Schoors, Danny, MD, PhD</creatorcontrib><creatorcontrib>Kemdem, Arsène, MD</creatorcontrib><creatorcontrib>Close, Laurent, MD</creatorcontrib><creatorcontrib>Vandenbossche, Jean-Luc, MD, PhD</creatorcontrib><creatorcontrib>Bechet, Serge, MD, PhD</creatorcontrib><creatorcontrib>Van Camp, Guy, MD, PhD</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Physical Education Index</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biochemistry Abstracts 1</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>The American journal of cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Droogmans, Steven, MD</au><au>Cosyns, Bernard, MD</au><au>D’haenen, Hugo, MD, PhD</au><au>Creeten, Edwin, MD</au><au>Weytjens, Caroline, MD</au><au>Franken, Philippe R., MD, PhD</au><au>Scott, Benjamin, MD</au><au>Schoors, Danny, MD, PhD</au><au>Kemdem, Arsène, MD</au><au>Close, Laurent, MD</au><au>Vandenbossche, Jean-Luc, MD, PhD</au><au>Bechet, Serge, MD, PhD</au><au>Van Camp, Guy, MD, PhD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Possible Association Between 3,4-Methylenedioxymethamphetamine Abuse and Valvular Heart Disease</atitle><jtitle>The American journal of cardiology</jtitle><addtitle>Am J Cardiol</addtitle><date>2007-11-01</date><risdate>2007</risdate><volume>100</volume><issue>9</issue><spage>1442</spage><epage>1445</epage><pages>1442-1445</pages><issn>0002-9149</issn><eissn>1879-1913</eissn><coden>AJCDAG</coden><abstract>Valvular heart disease, inducing valvular regurgitation, has been described in users of drugs such as anorectic agents and ergot derivates. 3,4-Methylenedioxymethamphetamine (MDMA; “ecstasy”) also leads in vitro to the proliferation of cardiac valvular interstitial cells by activation of the 5-hydroxytryptamine 2B receptor. The aim of this study was to determine the occurrence of valvulopathy in young adults taking MDMA. Twenty-nine subjects using or having used MDMA and 29 gender- and age-matched controls were blindly evaluated with echocardiography. Eight subjects (28%) who took MDMA had abnormal echocardiographic results using the United States Food and Drug Administration’s criteria for appetite suppressant–induced valvular heart disease, compared with none in the control group (p = 0.0045). Six (21%) subjects had mitral regurgitation of 1/4 and 4 (14%) of ≥2/4, compared with none in the control group (p = 0.002). The mean mitral regurgitant area ratios (jet/atrium) were 12 ± 9.8% and 5 ± 1.3%, respectively (p = 0.007). Tricuspid regurgitation ≥2/4 was present in 13 MDMA users (45%) and absent in controls (p <0.001). The mean tricuspid regurgitant area ratios were 19 ± 9.5% and 9 ± 4.5%, respectively (p <0.001). Four MDMA users (14%) had mild aortic regurgitation (p = 0.11). Valvular “strands” were present in 6 MDMA users (21%) and in none of the controls (p = 0.02). In conclusion, MDMA may lead to mild to moderate valvular heart disease and valvular strands.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>17950805</pmid><doi>10.1016/j.amjcard.2007.06.045</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-9149 |
| ispartof | The American journal of cardiology, 2007-11, Vol.100 (9), p.1442-1445 |
| issn | 0002-9149 1879-1913 |
| language | eng |
| recordid | cdi_proquest_journals_230369514 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Adult Biological and medical sciences Cardiology Cardiology. Vascular system Cardiovascular Cardiovascular disease Dose-Response Relationship, Drug Drug abuse Ecstasy Endocardial and cardiac valvular diseases Female Hallucinogens - adverse effects Heart Heart Valve Diseases - chemically induced Humans Logistic Models Male Medical sciences N-Methyl-3,4-methylenedioxyamphetamine - adverse effects Substance-Related Disorders - complications Young adults |
| title | Possible Association Between 3,4-Methylenedioxymethamphetamine Abuse and Valvular Heart Disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T16%3A59%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Possible%20Association%20Between%203,4-Methylenedioxymethamphetamine%20Abuse%20and%20Valvular%20Heart%20Disease&rft.jtitle=The%20American%20journal%20of%20cardiology&rft.au=Droogmans,%20Steven,%20MD&rft.date=2007-11-01&rft.volume=100&rft.issue=9&rft.spage=1442&rft.epage=1445&rft.pages=1442-1445&rft.issn=0002-9149&rft.eissn=1879-1913&rft.coden=AJCDAG&rft_id=info:doi/10.1016/j.amjcard.2007.06.045&rft_dat=%3Cproquest_cross%3E1374412131%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=230369514&rft_id=info:pmid/17950805&rft_els_id=S0002914907014634&rfr_iscdi=true |